Pharmaceutical News and Articles

UCB Announces Positive Results from GEMZ Phase 3 Study of Fenfluramine in CDKL5 Deficiency Disorder

Brussels, Belgium 27th June 2025 UCB, a global biopharmaceutical company, today announced that the phase 3 study investigating the safety and efficacy of adjunc

Breast Cancer Risk in Younger Women May Be Influenced by Hormone Therapy

Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. R

Amgen Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-line Gastric Cancer

Amgen (NASDAQ AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary en

FDA Approves Expanded Indications for GE HealthCare’s Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients

Emmaus Life Sciences Receives FDA Approval for Endari Label Enhancements

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Lower Risk of Alzheimer Disease Seen for Breast Cancer Survivors

Breast cancer survivors have a lower risk of Alzheimer disease (AD) compared with cancer-free controls, according to a study published online June 20 in JAMA Ne

FDA Approves Benlysta Autoinjector for Pediatric Patients With Active Lupus Nephritis

The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients 5 years of age with active lup

Liraglutide May Reduce Migraine Burden in Adults With Obesity, Migraine

For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and Migraine Disability Assessment (MID

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels for Breyanzi and Abecma